Multiple Analyses of G-Protein Coupled Receptor (GPCR) Expression in the Development of Gefitinib-Resistance in Transforming Non-Small-Cell Lung Cancer

Naoko Kuzumaki1,2*, Atsuo Suzuki2, Michiko Narita2, Takahiro Hosoya3, Atsumi Nagasawa2, Satoshi Imai2, Kohei Yamamizu4, Hiroshi Morita5, Tsutomu Suzuki6, Yohei Okada1, Hirotaka James Okano1, Jun K. Yamashita4, Hideyuki Okano1, Minoru Narita2*

1 Department of Physiology, Keio University, School of Medicine, Tokyo, Japan, 2 Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan, 3 Biological Systems Control Team, Biomedical Information Research Center, Tokyo, Japan, 4 Laboratory of Stem Cell Differentiation, Stem Cell Research Center, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan, 5 Faculty of Pharmaceutical Sciences, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan, 6 Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan

Abstract

There is increasing evidence that functional crosstalk between GPCRs and EGFR contributes to the progression of colon, lung, breast, ovarian, prostate and head and neck tumors. In this study, we performed multiple analyses of GPCR expression in a gefitinib-resistant non-small cell lung cancer (NSCLC) cell line, H1975, which harbors an L858R/T790M mutation. To determine the expression profile of mRNAs encoding 384 GPCRs in normal human lung fibroblast (NHLF) and H1975 cells, a GPCR-specific microarray analysis was performed. A heat-map of the microarray revealed considerable differences in the expression of GPCRs between NHLF and H1975 cells. From the GPCR expression list, we selected some GPCR agonists/antagonists to investigate whether the respective ligands could affect the growth of H1975 cells. Among them, treatment with either a selective agonist of adenosine A2a receptors, which were highly expressed in H1975 cell and another gefitinib-resistant NSCLC cells, HCC827GR cells or “small interfering RNA” (siRNA) targeting adenosine A2a receptors produced a significant decrease in cell viability of both H1975 and HCC827GR cells. Among up-regulated GPCRs in H1975 cells, Gs-, Gi- and Gq-coupled GPCRs were expressed almost equally. Among down-regulated GPCRs, Gi-coupled GPCRs were dominantly expressed in H1975 cells. The present results suggest that multilayered crosstalk between GPCRs and EGFR may play an important role in orchestrating downstream signaling molecules that are implicated in the development of gefitinib-resistant NSCLC.

Citation: Kuzumaki N, Suzuki A, Narita M, Hosoya T, Nagasawa A, et al. (2012) Multiple Analyses of G-Protein Coupled Receptor (GPCR) Expression in the Development of Gefitinib-Resistance in Transforming Non-Small-Cell Lung Cancer. PLoS ONE 7(10): e44368. doi:10.1371/journal.pone.0044368

Editor: Pan-Chyr Yang, National Taiwan University Hospital, Taiwan
Received September 10, 2011; Accepted August 2, 2012; Published October 29, 2012
Copyright: © 2012 Kuzumaki et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: naokokuzumaki@gmail.com (NK); narita@hoshi.ac.jp (Minoru Narita)

Introduction

Non-small-cell lung cancer (NSCLC) is the leading cause of death from cancer. While, chemotherapy can slightly prolong survival in patients with advanced disease, it is also associated with clinically significant adverse effects [1]. Epidermal growth factor receptor (EGFR) is a major target of molecular anti-NSCLC therapy [2]. Gefitinib targets the ATP cleft in the tyrosine kinase EGFR, which is overexpressed in 40–80 percent of NSCLC and many other epithelial cancers [3]. EGFR signaling is triggered by the binding of growth factors, such as EGF, which results in either the dimerization of EGFR molecules or heterodimerization with related receptors, such as HER2. Autophosphorylation and transphosphorylation of EGFRs through their tyrosine kinase domains recruits downstream effectors and activates signals for proliferation and cell-survival [4]. Mutations have been identified in the EGFR gene in specimens from patients with NSCLC who respond to EGFR inhibitors [5]. These mutations consist of small deletions that affect amino acids 746 through 750 (delE746-A750) or point mutations (most often leucine replaced by arginine at codon 858 [L858R]) [6,7,8]. These mutations modify downstream signaling and antiapoptotic mechanisms, and thus mediate oncogenic effects [9]. Both of these mutations make the tumor more sensitive to compounds that inhibit EGFR, most likely by repositioning critical residues that surround the ATP-binding cleft of the tyrosine kinase domain of the receptor, which stabilizes interactions with both ATP and its competitive inhibitors [6,7]. In our case, DNA sequencing of the EGFR gene in a tumor biopsy specimen at relapse showed a second point mutation that changed threonine to methionine at position 790 (T790M) of EGFR [5]. The efficacy of gefitinib is of limited duration, mainly due to drug resistance conferred by a second point mutation.

The activity of Akt, which is also known as protein kinase B (PKB), is stimulated by various growth factors, and this serine/threonine kinase plays evolutionarily conserved roles in many cellular functions, such as protein synthesis and cell growth [10,11]. It has been reported that EGFR inhibitor changes strong, transient Akt phosphorylation to weak, sustained Akt phosphorylation. Due to the low-pass filter characteristics of the Akt pathway, this leads to the stronger phosphorylation of S6, which is
a molecule downstream of Akt, than that in the absence of the inhibitor. Thus, EGFR inhibitor could act as a downstream activator of EGFR [12]. Taken together, these findings suggest that the process of gefitinib-resistance leads to the exacerbation of tumor cells.

A large body of evidence indicates that G protein-coupled receptors (GPCRs) play a crucial role in tumorigenesis, and are implicated in important steps in cancer progression from transformation, growth and survival to metastasis. Another important way that GPCRs contribute to tumorigenesis involves intensive crosstalk with a canonical pathway. There is considerable evidence that agonists of some GPCRs, through a process called transactivation, can activate growth factor receptor tyrosine kinases (RTKs) in the absence of added growth factor [13,14,15]. This is an important pathway that contributes to the growth-promoting activity of many GPCR ligands. On the other hand, recent findings have indicated that RTKs transduce signals through the use GPCR signaling molecules and RTK ligands themselves can transactivate GPCRs. To mediate tumor survival and proliferation, GPCRs may interact with EGFR downstream signaling pathways, including phosphatidylinositol 3-kinase (PI3K)/Akt, and Janus kinase/signal transducers and activators of transcription (Jak/Stat) pathways. Indeed, the functional crosstalk between GPCRs and EGFR contributes to the progression of colon, lung, breast, ovarian, prostate and head and neck tumors [16,17]. Thus, GPCR could be an excellent site for blocking tumorigenic signals, which would make GPCR-mediated functions promising therapeutic targets in drug development to achieve innovative intervention in NSCLC. In the present study, we performed multiple analyses of GPCR expression in a gefitinib-resistant NSCLC cell line, H1975.

Materials and Methods

Cell culture

The human non-small cell lung cancer cell (NSCLC) lines HCC827, NCI-H1975 (H1975; American Type Culture Collection Co., MD, USA) and HCC827GR were cultured in RPMI 1640 medium HEPES Modification (Sigma-Aldrich Co., MO, USA) with 10% fetal bovine serum (FBS; Invitrogen Life Technologies Co., CA, USA) and 1% penicillin-streptomycin (PS; Sigma Chemical Co.). Normal human lung fibroblast basal medium with insulin, rhFGF-B, GA-1000 and FBS (all from Takara Bio Inc., Tokyo, Japan). All cells were washed and cultured in drug-free medium until surviving cells were finally able to grow in 5 μM of gefitinib for 48 h in medium containing 10% fetal bovine serum. They were then cultured in drug-free medium for at least 1 week to eliminate gefitinib. Gefitinib-resistant cells are referred to as HCC827GR.

Establishment of the gefitinib-resistant cell line, HCC827GR

HCC827 cells were exposed to 1 μM of gefitinib for 48 h in medium containing 10% fetal bovine serum. They were then washed and cultured in drug-free medium until surviving cells were 80% confluent. These cells were then re-exposed to increasing concentrations of gefitinib (from 1 to 5 μM). Cells were finally able to grow in 5 μM gefitinib were obtained 1.5 month after initial exposure. The established resistant cells were maintained in medium containing 1 μM of gefitinib. For all in vitro studies, resistant cells were cultured in drug-free medium for at least 1 week to eliminate gefitinib. Gefitinib-resistant cells are referred to as HCC827GR.

Reagents

The reagents used in the present study were gefitinib (Toronto Research Chemicals Inc., Canada), [Arg9]-vasopressin acetate salt (Sigma Chemical Co., St. Louis, MO, USA), angiotensin II (Sigma Chemical Co.), 2-(methylthio) adenosine 5’-triphosphate tetrasodium salt hydrate (Sigma Chemical Co.), beraprost sodium (TORYA Industries Inc., Tokyo, Japan), a-methyl-5-(2-thienyl-methoxy)-1H-Indole-3-ethanamine monohydrochloride (BW723C86; Sigma Chemical Co.), 2-p-(2-carboxyethyl) phenethylamino-5’-N-ethylcarbamoaoxyadenosine hydrochloride hydrate (CGS-21680; Sigma Chemical Co.), 7-(2-phenylethyl)-5-amino-2-(2-arylpyrazolo-[1,3-c]-1,2,4-triazolo [1,5-e] pyrimidine (SCH-58261; Sigma Chemical Co.).

Cell viability assay

Cells viability was determined by the 3-(4,5-diethyliothiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. Twenty μL of MTT solution (5 mg/mL) was added to each well of the culture medium. After incubation for another 2 hr, the medium was removed, and 100 μL of DMSO were added to resolve formazan crystals. Optical density was measured using a microplate reader at an absorption wavelength 600 nm. In each experiment, three replicates were prepared for each sample. The proportion of living cells was determined based on the difference in absorbance between samples and controls.

GPCR TaqMan Array

A commercially available TaqMan Array Human GPCR card (Applied Biosystems Inc., Foster City, CA, USA) which allows us to quantify the expression of mRNAs that encode GPCRs from 50 subfamilies (343 receptors, not including the odorant, olfactory, gustatory and pheromone receptors), was used with RNA extracted from NHLF and H1975 cells. Total RNA, obtained from NHLF and H1975 cells, was extracted using the mirVanaTM miRNA Isolation Kit (Applied Biosystems Inc.). For this assay, cDNA was prepared with a high-capacity RNA to cDNA kit (Applied Biosystems Inc.). Each port was loaded with cDNA (from 1.5 μg of RNA) and TaqMan Gene Expression Master Mix (Applied Biosystems Inc.) according to the manufacturer’s instructions. The plate was analyzed using SDS2.3 and RQ Manager 1.2 software provided by Applied Biosystems. Cycle times were normalized to the housekeeping gene GAPDH. A comparative Ct approach was used to quantify the relative levels of mRNA using RQ 1.2 software. Relative expression levels were calculated as 2^ΔCt. The results for each GPCR were examined, and if the sample had a calculated threshold below 0.1, it was considered to be undetectable. In these cases, for data processing purposes, the cycle number was set at 35.0.

RNA preparation and semi-quantitative analysis by reverse transcription-polymerase chain reaction (RT-PCR)

Total RNA in NHLF, H1975, HCC827 and HCC827GR was extracted using the SV Total RNA Isolation system (Promega, Madison, WI) following the manufacturer’s instructions. Purified total RNA was quantified spectrophotometrically at A260. To prepare first-strand cDNA, 1 μg of RNA was incubated in 100 μL of buffer containing 10 mM dithiothreitol, 2.5 mM MgCl2, dNTP mixture, 200 U of reverse transcriptase II (Invitrogen), and if the sample had a calculated threshold below 0.1, it was considered to be undetectable. In these cases, for data processing purposes, the cycle number was set at 35.0.
was at 72°C for 7 min. The mixture was run on 2% agarose gel electrophoresis with the indicated markers and primers for the internal standard glyceraldehyde-3-phosphate dehydrogenase. The agarose gel was stained with ethidium bromide and photographed with UV transillumination. The intensity of the bands was analyzed and semi-quantified by computer-assisted densitometry using ImageJ software.

Sample preparation and Western blotting

Cells were solubilized with buffer containing 20 mM Tris-HCl (pH 7.4), 0.3% (w/v) Triton, 3 mM MgCl₂, 1 M sucrose, 5 mM α-ME, and 1/1,000 protease inhibitor for 15 min. Cell lysates were centrifuged at 2,350 g for 10 min at 4°C and the supernatant was retained as the lysate fraction for Western blotting. An aliquot of sample was diluted with an equal volume of 2× electrophoresis sample buffer (Protein Gel Loading Dye-2X, Amresco, Solon, OH) containing 2% sodium dodecyl sulfate (SDS) and 10% glycerol with 0.2 M dithiothreitol. Proteins (7 µL/lane) were separated by size on 4–20% SDS-polyacrylamide gradient gel and transferred to nitrocellulose membranes in Tris-glycine buffer containing 25 mM Tris and 192 mM glycine. For immunoblot detection, membranes were blocked in Tris-buffered saline (TBS) containing 1% nonfat milk (Bio-Rad Laboratories, Hercules, CA, USA) containing 0.1% Tween 20 (Research Biochemicals, Inc., MA, USA) for 1 h at room temperature.

Figure 1. Effect of gefitinib on the growth of gefitinib-sensitive (HCC827) or resistant (H1975) NSCLC cell lines. HCC827 (a) or H1975 (b) cells were incubated for 2 days with gefitinib, and then cell viability was measured (**p<0.001 vs. non-treated group).
doi:10.1371/journal.pone.0044368.g001

Figure 2. Pearson’s correlation scatter plot of GPCR levels in NHLF and H1975 cells (R = 0.7799). Human GPCR expression was analyzed by microarrays.
doi:10.1371/journal.pone.0044368.g002
Figure 3. Heatmap of 384 human GPCR differentially expressed in H1975 cells compared to NHLF cells. Each GPCR is shown as a single bar based on their Ct values and color coding is shown below, with a gradient from green (negative and lowest Ct values) to red (positive and highest Ct values).

doi:10.1371/journal.pone.0044368.g003
Table 1. G-coupled GPCR that were up-regulated in H1975 compared to NHLF (≥ 2-fold change).

(a) Gs

| Symbol   | Description                                      | H1975/NHLF fold difference | Coupling |
|----------|--------------------------------------------------|-----------------------------|----------|
| GPR87    | G protein-coupled receptor 87                    | 425.1676                    | Gs       |
| ADORA2A  | adenosine A2a receptor                            | 90.3941                     | Gs       |
| GIPR     | gastric inhibitory polypeptide receptor           | 13.2001                     | Gs       |
| CALCR    | calcitonin receptor                               | 13.1582                     | Gs       |
| ADORA2B  | adenosine A2b receptor                            | 10.9389                     | Gs       |
| ADRB2    | adrenergic beta-2 receptor                        | 8.849                        | Gs       |
| VIPR1    | vasoactive intestinal peptide receptor 1          | 8.7399                      | Gs       |
| LPHN1    | latrophilin 1                                    | 5.4757                      | Gs       |
| ADRB1    | adrenergic receptor beta 1                        | 4.7792                      | Gs       |
| HTR7     | 5-hydroxytryptamine (serotonin) receptor 7        | 4.3725                      | Gs       |
| P2RY11   | purinergic receptor P2Y G-protein coupled 11      | 3.5613                      | Gs,Gq    |
| MC1R     | melanocortin 1 receptor                           | 2.3968                      | Gs       |
| MC4R     | melanocortin 4 receptor                           | 2.2711                      | Gs       |
| DRD5     | dopamine receptor D5                              | 2.0623                      | Gs       |

(b) Gi

| Symbol   | Description                                      | H1975/NHLF fold difference | Coupling |
|----------|--------------------------------------------------|-----------------------------|----------|
| PPYR1    | pancreatic polypeptide receptor 1                | 15.2541                     | Gi       |
| AGTRL1   | angiotensin II receptor-like 1                    | 13.8131                     | Gi       |
| VN1R2    | vomeronasal 1 receptor 2                          | 11.9937                     | Gi       |
| EDG4     | lysophosphatic acid receptor 2                    | 10.4805                     | Gi       |
| EDG8     | sphingosine-1-phosphate receptor 5                | 8.1024                      | Gi       |
| HTR1D    | 5-hydroxytryptamine (serotonin) receptor 1D       | 7.4536                      | Gi       |
| OPR1     | olate receptor-like 1                             | 6.594                       | Gi       |
| CHRM4    | cholinergic receptor, muscarinic 4                | 5.9843                      | Gi       |
| OR7C2    | olfactory receptor family 7 subfamily C member 2  | 5.467                       | Gi       |
| PTAFR    | platelet-activating factor receptor               | 2.8268                      | Gi,Gq    |
| F2RL1    | coagulation factor II (thrombin) receptor-like 1  | 2.7511                      | Gi,Gq    |
| GNRHR    | onadotropin-releasing hormone receptor             | 2.669                       | Gi,Gq    |
| ADORA3   | adenosine A3 receptor                             | 2.5344                      | Gi       |
| CCR4     | chemokine (C-C motif) receptor 4                  | 2.4829                      | Gi       |
| SSTR2    | somatostatin receptor 2                           | 2.4233                      | Gi       |
| PTGER1   | prostaglandin E receptor 1                        | 2.2708                      | Gi,Gq    |
| SSTR3    | somatostatin receptor 3                           | 2.2642                      | Gi       |
| EDG6     | lysophosphatidic acid G-protein-coupled receptor 6| 2.0191                      | Gi       |

(c) Gq

| Symbol   | Description                                      | H1975/NHLF fold difference | Coupling |
|----------|--------------------------------------------------|-----------------------------|----------|
| P2RY2    | purinergic receptor P2Y G-protein coupled 2       | 209.5184                    | Gq       |
| FZD3     | frizzled homolog 3 (Drosophila)                   | 137.3562                    | Gq       |
| EMR2     | efg-like module containing mucin-like hormone receptor-like 2 | 88.5791 | Gq |
| LTB4R    | leukotriene B4 receptor                           | 41.6841                     | Gq       |
| FPR1     | formyl peptide receptor 1                         | 23.6083                     | Gq       |
| LTB4R2   | leukotriene B4 receptor 2                         | 8.6323                      | Gq       |
| MRGPRX2  | MAS-related GPR member X2                         | 7.3656                      | Gq       |
| FZD9     | frizzled homolog 9 (Drosophila)                   | 6.258                       | Gq       |
| CHRM5    | cholinergic receptor muscarinic 5                 | 4.1532                      | Gq       |
| P2RY11   | purinergic receptor P2Y G-protein coupled 11      | 3.5613                      | Gq,Gs    |
| CHRM3    | cholinergic receptor muscarinic 3                 | 3.2644                      | Gq       |
### Table 1. Cont.

| Symbol | Description | H1975/NHLF fold difference | Coupling |
|--------|-------------|----------------------------|----------|
| PTAFR  | platelet-activating factor receptor | 2.8268 | Gq,Gi |
| F2RL1  | coagulation factor II (thrombin) receptor-like 1 | 2.7511 | Gq,Gi |
| GNRRH  | onadotropin-releasing hormone receptor | 2.669 | Gq,Gi |
| P2RY4  | pyrimidinergic receptor P2Y G-protein coupled, 4 | 2.5966 | Gq |
| FFAR2  | free fatty acid receptor 2 | 2.5666 | Gq |
| PTGER1 | prostaglandin E receptor 1 | 2.2708 | Gq,Gi |

doi:10.1371/journal.pone.0044368.t001

### Table 2. G-coupled GPCR that were down-regulated in H1975 compared to NHLF (0.5 ≤ fold change).

| Symbol | Description | H1975/NHLF fold difference | Coupling |
|--------|-------------|----------------------------|----------|
| PTGIR  | prostaglandin I2 (prostacyclin) receptor | 0.0005 | Gs |
| PTGER2 | prostaglandin E receptor 2 | 0.0096 | Gs |
| EDG5   | sphingosine-1-phosphate receptor 2 | 0.1995 | Gs |
| LGR7   | relaxin/insulin-like family peptide receptor 1 | 0.3015 | Gs |
| AVPR2  | arginine vasopressin receptor 2 | 0.4646 | Gs |
| VIPR2  | vasoactive intestinal peptide receptor 2 | 0.4674 | Gs |
| F2RL2  | coagulation factor II (thrombin) receptor-like 2 | 0.0152 | Gi |
| EDG2   | lysophosphatidic acid receptor 1 | 0.0162 | Gi |
| CHRM2  | cholinergic receptor muscarinic 2 | 0.0323 | Gi |
| F2R    | coagulation factor II (thrombin) receptor | 0.0342 | Gi |
| SSTR1  | somatostatin receptor 1 | 0.0344 | Gi |
| P2RY12 | purinergic receptor P2Y G-protein coupled 12 | 0.0629 | Gi |
| OXTR   | oxytocin receptor | 0.1066 | Gi,Gq |
| FZD1   | frizzled homolog 1 (Drosophila) | 0.1587 | Gi |
| CCR5   | chemokine (C-C motif) receptor 5 | 0.1621 | Gi |
| EDG3   | sphingosine-1-phosphate receptor 3 | 0.1654 | Gi |
| CCR1   | chemokine (C-C motif) receptor 1 | 0.1975 | Gi |
| BDKRB1 | bradykinin receptor B1 | 0.2243 | Gi,Gq |
| CCR10  | chemokine (C-C motif) receptor 10 | 0.2559 | Gi |
| AVPR1A | arginine vasopressin receptor 1A | 0.0071 | Gq |
| ADRA1D | adrenergic alpha 1D receptor | 0.0086 | Gq |
| NTSR1  | neurotensin receptor 1 | 0.0159 | Gq |
| NMUR1  | neuromedin U receptor 1 | 0.0247 | Gq |
| P2RY1  | purinergic receptor P2Y G-protein coupled | 0.0784 | Gq |
| OXTR   | oxytocin receptor | 0.1066 | Gq,Gi |
| ADRA1B | adrenergic alpha 1B receptor | 0.1864 | Gq |
| BDKRB1 | bradykinin receptor B1 | 0.2243 | Gq,Gi |
| AVPR1B | arginine vasopressin receptor 1B | 0.3674 | Gq |

doi:10.1371/journal.pone.0044368.t002
were added to the 96-well. After that, cells (5 × 10^5) mixed with RNAimax (Invitorogen) pre-diluted in Opti-MEM. Specific siRNA were diluted in Opti-MEM (Invitorogen) and the growth of H1975 cells (detected by MTT assay).

Effect of the tyrosine kinase inhibitor gefitinib on the growth of non-small cell lung cancer (NSCLC) cells

Results

Statistical Analysis

All data are presented as the mean ± S.E.M. The statistical significance of differences between groups was assessed by one-way analysis of variance (ANOVA) followed by the Bonferroni/Dunn multiple comparison test. The statistical significance of differences between two groups was assessed with Student’s t-test.

Effect of the tyrosine kinase inhibitor gefitinib on the growth of non-small cell lung cancer (NSCLC) cells

Addition of the tyrosine kinase inhibitor gefitinib (0.0001 μM–1 μM) to HCC827 cells, which have been classified as the gefitinib-sensitive NSCLC cell line [5], for 2 days produced a concentration-dependent decrease in tumor cell growth (Figure 1a-i, p<0.001 vs. non-treated group). In contrast, the addition of gefitinib (0.0001 μM–1 μM) for 2 days did not affect the growth of H1975 cells (Figure 1a-ii).

Different expression of GPCRs between NHLF and H1975 cells

To profile the expression of mRNAs encoding 384 GPCRs in NHLF and H1975 cells, a TaqMan GPCR-specific microarray analysis was performed (Figures 2, 3, Figures S1-1, S1-2, S1-3 for the list of GPCR genes in the array). The scatter plot showed that there were many more up-regulated GPCRs than down-regulated GPCRs in H1975 cells compared to NHLF. A heat-map of the microarray revealed considerable differences in the expression of GPCRs between NHLF and H1975 cells (Figures 2, 3).

Changes in the expression ratios of Gα subunits (Gs, Gi and Gq) in H1975 cells

The expression patterns of Gα subunits among up- or down-regulated GPCRs of H1975 cells compared to NHLF were assigned to the following groups: up-regulated Gs-coupled GPCR (Table 1-a), up-regulated Gi-coupled GPCR (Table 1-b), up-regulated Gq-coupled GPCR (Table 1-c), down-regulated Gs-coupled GPCR (Table 2-a), down-regulated Gi-coupled GPCR (Table 2-b) and down-regulated Gq-coupled GPCR (Table 2-c).

The mRNA and its protein expressions of GRP87, which was the most up-regulated GPCR found in the GPCR array, were significantly up-regulated in H1975 cells compared to those in NHLF cells (Figure 4a: p<0.01 vs. NHLF, Figure 4b: p<0.001 vs. NHLF).

Among up-regulated GPCRs in H1975 cells, Gs-, Gi- and Gq-coupled GPCRs were expressed almost equally. Among down-regulated GPCRs, Gi-coupled GPCRs were dominantly expressed in H1975 cells (Figure 5).

Effects of a selective GPCR agonist or antagonist on the growth of gefitinib-resistant H1975 cells

From the GPCR expression list, some commercially available GPCR agonist/antagonist were selected to investigate whether the respective ligands affected the growth of H1975 cells (Figure S2). An adenosine A2a receptor (CGS-21680), an angiotensin II receptor-like 1 agonist (angiotensin II) and a purinergic receptor P2Y G-protein coupled 2 agonist (2-(methylthio) adenosine 5’-triphosphate tetrasodium salt hydrate), which were all agonists of up-regulated GPCRs in the microarray list, had no effect on tumor cell growth. Similarly, cell growth was not affected by a prostaglandin I2 receptor (IP) agonist (beraprost sodium), a 5-
hydroxytryptamine receptor 2B agonist (BW723C86) and an arginine vasopressin receptor 1A agonist ([Arg⁸]-vasopressin acetate salt), which were all classified as “down-regulated GPCRs”. In contrast, addition of the selective adenosine A2a receptor antagonist SCH-58261 (10 nM–10 μM) for 7 days (Figure 6a) produced a concentration-dependent decrease in H1975 cell growth (p < 0.01, p < 0.001 vs. non-treated group).

We next performed to transduce siRNA targeting adenosine A2a receptors into H1975 cells. Cells were harvested for detection of the adenosine A2a receptor mRNA level semi-quantitatively by RT-PCR at 72 h post-transfection. The adenosine A2a receptor expression in the presence of siRNA targeting adenosine A2a receptors was down-regulated by 90% compared to non-treatment (data not shown). Under these conditions, treatment with siRNA targeting adenosine A2a receptors produced a significant decrease in H1975 cell growth (Figure 6b: p < 0.001 vs. non-treated group).

Role of adenosine A2a receptors in the growth of gefitinib-resistant HCC827GR cells

To confirm the function of adenosine A2a receptors on gefitinib-resistance to NSCLC, we generated another gefitinib-resistant HCC827GR cells by exposing HCC827 cells to increasing concentrations of gefitinib for 1.5 month. According

---

**Figure 5.** Expression ratio of Gα subunit (Gs, Gi and Gq) in H1975 cells. The percentage of expression pattern of Gα subunit (Gs: red, Gi: blue and Gq: green) in the up- or down-regulated GPCRs of H1975 cells compared to NHLF is shown.

**Figure 6.** Effects of a selective antagonist of adenosine A2a receptors or siRNA targeting adenosine A2a receptors on the growth of H1975 cells. (a) H1975 cells were incubated for 7 days with the selective adenosine A2a receptor antagonist SCH-58261 (10 nM–10 μM), and then cell viability was measured (**p < 0.01, ***p < 0.001 vs. non-treated group). (b) Treatment with siRNA targeting adenosine A2a receptors to H1975 cells for 3 days significantly decreased cell viability of H1975 cells (**p < 0.01 vs. non-treated group).
to a sequence analysis, HCC827GR cells had second point mutation, due to caused mainly drug resistance, 2369 C>T in EGFR exon 20-21, which led to the transitions Thr790Met (Figure 7a-i). Therefore, the addition of gefitinib (0.01 μM–1μM) for 2 days did not affect the growth of HCC827GR cells (Figure 7a-ii). The expression of adenosine A2a receptor mRNA was dramatically increased in HCC827GR cells compared to HCC827 and NHLF cells (Figure 7b, p<0.001 vs. NHLF). Under these conditions, the selective adenosine A2a receptor antagonist SCH-58261 (10 nM–10 μM) for 7 days produced a concentration-dependent decrease in HCC827GR cell growth (Figure 7c, p<0.05, p<0.001 vs. non-treated group). Furthermore, treatment with siRNA targeting adenosine A2a receptors to HCC827GR cells for 3 days significantly decreased cell viability of HCC827GR cells (***p<0.001 vs. non-treated group).

**Discussion**

GPCRs have traditionally been associated with many of the functions of differentiated, post-mitotic cells. On the other hand, GPCRs are also expressed in proliferating cells and contribute to embryogenesis, tissue remodeling and repair, inflammation, angiogenesis, normal cell growth and cancer.

Among them, protease-activated receptors (PARs), chemokine receptors and receptors for bio-active lipids such as LPA and sphingosine-1-phosphate (S1P) have been implicated in aberrant cell proliferation in a wide variety of cancer cells. Furthermore, neuropeptides such as endothelin, bradykinin, neuromedin B, cholecystokinin and angiotensin II activate their cognate GPCRs to stimulate cell proliferation in various cell types, and play a crucial role in many aggressive human cancers, including small-cell lung cancer (SCLC), pancreatic cancer, head and neck squamous cell carcinoma (HNSCC), and prostate cancer [18,19].
However, there have been few reports about the critical role of GPCRs in gefitinib-resistant NSCLC cells, such as H1975 cells. A better understanding of the role of GPCRs in NSCLC can come from multiple analyses for gene-expression profiling. Microarray studies are likely to be useful tools for this purpose. Therefore, we performed a GPCR microarray analysis for gefitinib-resistant H1975 cells compared to normal human lung fibroblasts. By profiling the expression of mRNAs encoding GPCRs, we found a large number of GPCRs overexpressed in H1975 cells. It has been recognized that many GPCRs that were overexpressed in various cancer types promote the growth of tumor cells when activated by circulating or locally produced ligands. Among GPCRs, GRP87 was listed as the most up-regulated GPCR in the present GPCR array. After this array, we validated the up-regulated expression of GRP87 mRNA and its protein using RT-PCR and western blotting, compared to those observed in NHLF cells. In H1975 cells, Ge-, Gi- and Gq-coupled GPCRs were overexpressed to almost the same extent, whereas some Gi-coupled GPCRs were down-regulated in H1975 cells.

The activation of A2a receptors has been reported to lead to immunosuppressive effects, which decreases anti-tumoral immunity and thus encourages tumor growth. In behavioral studies, it has been suggested that A2a antagonists should be added to immunotherapeutic protocols for cancer to enhance tumor immunotherapy. These compounds have already been shown to be safe in trials with A2a antagonists in treatment of Parkinson’s disease [20]. In the present study, we investigated whether the specific agonists/antagonist which act on GPCRs that were up-regulated or down-regulated in H1975 cells could affect the growth of H1975 cells. Among the GPCRs listed, a selective antagonist of adenosine A2a receptor, which was one of the commercially available ligands for GPCRs overexpressed in H1975 cells, produced a dose-dependent decrease in H1975 cell viability. Similar to the antagonist, treatment with siRNA targeting adenosine A2a receptors produced a significant decrease in H1975 cell viability. To further investigate the role of adenosine A2a receptors in gefitinib-resistance to NSCLC, we generated another gefitinib-resistant clone by exposing gefitinib to gefitinib-sensitive NSCLC cells, HCG827 cells. Like H1975 cells, the expression of adenosine A2a receptor mRNA was dramatically increased in gefitinib-resistant HCG827GR cells compared to HCG827 and NHLF cells. Under these conditions, treatment with either the selective adenosine A2a receptor antagonist or siRNA targeting adenosine A2a receptors produced a significant decrease in HCG827GR cell growth. These findings suggest that, although further in vivo studies are still needed, the ability to interfere with adenosine A2a receptors may provide unique opportunities for the prevention and treatment of NSCLC. On the other hand, selective agonists for adenosine A2a receptor, angiotensin II receptor-like 1, purinergic receptor P2Y G-protein coupled 2, prostaglandin F2 receptor (FP), 5-hydroxytryptamine receptor 2B and arginine vasopressin receptor 1A had no effect on H1975 cell viability, which reflects the complex functions of GPCRs expressed in these cells. Many of the ligands or inhibitors for GPCRs that were up- or down-regulated in H1975 cells were not available for the present study. For instance, it is considered that GPR37, which was the largest overexpressed GPCR in H1975 cells, plays a crucial role in the p53-dependent survival of cancer cells exposed to DNA damage [21]. However, the specific ligand and its antagonist have not yet been identified. Since there is no doubt that GPCRs may be key players in the regulation of various pathophysiological responses, including cancer development and progression, it is likely that approaches involving interference with RNA will allow us to better understand the specialized functions of GPCRs expressed in gefitinib-resistant NSCLC cells.

In conclusion, we demonstrated that a large number of GPCRs were up-regulated while some were down-regulated via functional crosstalk between EGFR downstream and GPCR transcription in the development of gefitinib-resistance in NSCLC.

Supporting Information

Figure S1 List of GPCR gene symbols in microarray. TaqMan Array Human GPCR card which allows us to quantify the expression of mRNAs that encode GPCRs from 50 subfamilies (343 receptors, not including the odorant, olfactory, gustatory and pheromone receptors), was used. (PDF)

Figure S2 Effects of several GPCR agonists on the growth of H1975 cells. H1975 cells were incubated for 2 days with each GPCR ligand (1, 10 µM) and MTT assay was then performed. The cell viability data represents the mean with S.E.M. of 5 independent samples. (PDF)

Author Contributions

Conceived and designed the experiments: NK Minoura Narita. Performed the experiments: NK AS Michiko Narita TH AN KY YO. Analyzed the data: NK AS SI KY HM. Contributed reagents/materials/analysis tools: HJO JKY HO TS. Wrote the paper: NK Minoura Narita.

References

1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92–98.
2. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, et al. (2002) The activation of A2a receptors has been reported to lead to immunosuppressive effects, which decreases anti-tumoral immunity and thus encourages tumor growth. In behavioral studies, it has been suggested that A2a antagonists should be added to immunotherapeutic protocols for cancer to enhance tumor immunotherapy. These compounds have already been shown to be safe in trials with A2a antagonists in treatment of Parkinson’s disease [20]. In the present study, we investigated whether the specific agonists/antagonist which act on GPCRs that were up-regulated or down-regulated in H1975 cells could affect the growth of H1975 cells. Among the GPCRs listed, a selective antagonist of adenosine A2a receptor, which was one of the commercially available ligands for GPCRs overexpressed in H1975 cells, produced a dose-dependent decrease in H1975 cell viability. Similar to the antagonist, treatment with siRNA targeting adenosine A2a receptors produced a significant decrease in H1975 cell viability. To further investigate the role of adenosine A2a receptors in gefitinib-resistance to NSCLC, we generated another gefitinib-resistant clone by exposing gefitinib to gefitinib-sensitive NSCLC cells, HCG827 cells. Like H1975 cells, the expression of adenosine A2a receptor mRNA was dramatically increased in gefitinib-resistant HCG827GR cells compared to HCG827 and NHLF cells. Under these conditions, treatment with either the selective adenosine A2a receptor antagonist or siRNA targeting adenosine A2a receptors produced a significant decrease in HCG827GR cell growth. These findings suggest that, although further in vivo studies are still needed, the ability to interfere with adenosine A2a receptors may provide unique opportunities for the prevention and treatment of NSCLC. On the other hand, selective agonists for adenosine A2a receptor, angiotensin II receptor-like 1, purinergic receptor P2Y G-protein coupled 2, prostaglandin F2 receptor (FP), 5-hydroxytryptamine receptor 2B and arginine vasopressin receptor 1A had no effect on H1975 cell viability, which reflects the complex functions of GPCRs expressed in these cells. Many of the ligands or inhibitors for GPCRs that were up- or down-regulated in H1975 cells were not available for the present study. For instance, it is considered that GPR37, which was the largest overexpressed GPCR in H1975 cells, plays a crucial role in the p53-dependent survival of cancer cells exposed to DNA damage [21]. However, the specific ligand and its antagonist have not yet been identified. Since there is no doubt that GPCRs may be key players in the regulation of various pathophysiological responses, including cancer development and progression, it is likely that approaches involving interference with RNA will allow us to better understand the specialized functions of GPCRs expressed in gefitinib-resistant NSCLC cells.

In conclusion, we demonstrated that a large number of GPCRs were up-regulated while some were down-regulated via functional crosstalk between EGFR downstream and GPCR transcription in the development of gefitinib-resistance in NSCLC.

Supporting Information

Figure S1 List of GPCR gene symbols in microarray. TaqMan Array Human GPCR card which allows us to quantify the expression of mRNAs that encode GPCRs from 50 subfamilies (343 receptors, not including the odorant, olfactory, gustatory and pheromone receptors), was used. (PDF)

Figure S2 Effects of several GPCR agonists on the growth of H1975 cells. H1975 cells were incubated for 2 days with each GPCR ligand (1, 10 µM) and MTT assay was then performed. The cell viability data represents the mean with S.E.M. of 5 independent samples. (PDF)

Author Contributions

Conceived and designed the experiments: NK Minoura Narita. Performed the experiments: NK AS Michiko Narita TH AN KY YO. Analyzed the data: NK AS SI KY HM. Contributed reagents/materials/analysis tools: HJO JKY HO TS. Wrote the paper: NK Minoura Narita.
dimerization and surface density measurements in single cells. Proc Natl Acad
Sci U S A 108: 7016–7021.
16. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr (2000) Estrogen-induced
activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog,
GPR30, and occurs via trans-activation of the epidermal growth factor receptor
through release of HB-EGF. Mol Endocrinol 14: 1649–1660.
17. Hart S, Fischer OM, Prenzel N, Zwick-Wallasch E, Schneider M, et al. (2005)
GPCR-induced migration of breast carcinoma cells depends on both EGFR signal
transactivation and EGFR-independent pathways. Biol Chem 386: 845–855.
18. Lappano R, Maggiolini M G protein-coupled receptors: novel targets for drug
discovery in cancer. Nat Rev Drug Discov 10: 47–60.
19. Dorsam RT, Gutkind JS (2007) G-protein-coupled receptors and cancer. Nat
Rev Cancer 7: 79–94.
20. Jenner P (2005) Istradefylline, a novel adenosine A2A receptor antagonist, for
the treatment of Parkinson’s disease. Expert Opin Investig Drugs 14: 729–738.
21. Zhang Y, Qian Y, Lu W, Chen X (2009) The G protein-coupled receptor 87 is
necessary for p53-dependent cell survival in response to genotoxic stress. Cancer
Res 69: 6049–6056.